



Media Contact
Dan McFadden
dmcfadden@oculusis.com
(425) 836-3103

DR. ANDRES GUTIERREZ OF MEXICAN MINISTRY OF HEALTH JOINS OCULUS ADVISORY BOARD

PETALUMA, CA (September 2, 2003)— Oculus Innovative Sciences (www.oculusis.com), CEO and founder, Hoji Alimi, today announced the addition of Andrés A. Gutiérrez, MD, PhD, to the Oculus advisory board.

Dr. Gutiérrez, who is the head of the cell therapy unit of the Mexican Ministry of Health's National Center of Rehabilitation, is an experienced medical specialist who has been engaged in pioneering research since the beginning of his career. In 1997, he was appointed head of the gene therapy lab at the National Cancer Institute (NCI) of Mexico. Prior to his current appointment with the cell therapy unit, Dr. Gutiérrez and his unit, were instrumental in the advancement of studies in the area of innovative adenoviral vectors in experimental models of cancer as well as the study of molecular abnormalities in hereditary cancers. During this past decade as well, he has published more than 20 papers in various international journals and books.

Shortly, Dr. Gutiérrez anticipates a peer-journal review of his latest paper focusing on the research he conducted on Oculus's non-toxic disinfectant/antiseptic, Microcyn 60. This disinfectant recently received approval from Mexico's Ministry of Health for distribution and sale in Mexico.

"It has taken me over ten years to pull together this excellent research team and the appropriate facilities for my studies in Mexico," said Dr. Gutiérrez, "So now, being appointed to the advisory board at Oculus represents both an honor and an exciting challenge in my career."

CEO and founder of Oculus, Hoji Alimi, added, "Dr. Gutiérrez represents the absolute cutting edge in terms of medical research that is being conducted in Mexico. His scientific knowledge is extraordinary and Oculus, as a result, will benefit greatly from his guidance."

About Oculus

Oculus Innovative Sciences, headquartered in Petaluma, California, is pioneering innovative services and technologies that can improve patient health worldwide. The company has at its foundation two

wholly owned subsidiaries, MicroMed Consulting Services and AquaMed Technologies. Oculus has overseen the evolution of the Microcyn 60 disinfectant from technology to product as well as the development of an anti-cancer drug (L3) that shows promise in the prevention of many aggressive cancers including cervical cancer and melanomas. This same L3 compound has great potential in other applications based on its cell growth inhibition characteristics such as the drug-eluting stent products reducing restenosis. For more information, please visit us at www.oculusis.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. These forward-looking statements relate to, among other things, plans and timing for the introduction of our products, statements about future market conditions, supply and demand conditions, revenues, gross margins, operating expenses, profits and other expectations, intentions and plans contained in this press release that are not historical fact. Our expectations as expressed in this press release depend upon our ability to develop, manufacture and supply products that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in the health sciences market. In light of the many risks and uncertainties surrounding this market, you should understand that we cannot assure you that the forward-looking statements contained in this press release will be realized.